SAN DIEGO, April 28 2020 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders,
today announced that the company will participate in two
upcoming investor conferences.
Details of the company's participation are as follows:
- 2020 6th Annual SunTrust Robinson Humphrey (STRH)
Life Sciences Summit
Details: Viking management will
participate in a fireside chat and 1-on-1 meetings
Conference Date: May 5-6, 2020
Fireside Chat Time/Date: 3:00 p.m.
Eastern on Wednesday, May 6, 2020
Format: Virtual Conference
- UBS Virtual Global Healthcare Conference
2020
Details: Viking management will deliver a corporate
presentation and participate in 1-on-1 meetings
Conference Date: May 18-20, 2020
Presentation Time/Date: 3:00 p.m.
Eastern on Monday, May 18, 2020
Format: Virtual Conference
About Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical
company focused on the development of novel, orally available,
first-in-class or best-in-class therapies for the treatment of
metabolic and endocrine disorders. Viking's research and
development activities leverage its expertise in metabolism to
develop innovative therapeutics designed to improve patients'
lives. The company's clinical programs include VK2809, a
novel, orally available, small molecule selective thyroid hormone
receptor beta agonist for the treatment of lipid and metabolic
disorders, including NASH. In a Phase 2 trial for the
treatment of NAFLD and elevated LDL-C, patients who received VK2809
demonstrated statistically significant reductions in LDL-C and
liver fat content compared with patients who received
placebo. The company is also developing VK0214, a novel,
orally available, small molecule selective thyroid hormone receptor
beta agonist for the treatment of X-linked adrenoleukodystrophy
(X-ALD).
Viking's other programs include VK5211, an orally available,
non-steroidal selective androgen receptor modulator. In a
Phase 2 trial in patients recovering from hip fracture, patients
who received VK5211 experienced significant improvements in
measures of lean body mass compared with patients who received
placebo. Other programs also include two earlier-stage
programs targeting metabolic diseases and anemia. The company
holds exclusive worldwide rights to a portfolio of five therapeutic
programs, including those noted above, which are based on small
molecules licensed from Ligand Pharmaceuticals Incorporated.
Follow Viking on Twitter @Viking_VKTX.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-in-upcoming-investor-conferences-301047863.html
SOURCE Viking Therapeutics, Inc.